Laura Waters

Summary

Country: UK

Publications

  1. ncbi request reprint Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Laura Waters
    Department of GU HIV Medicine, Mortimer Market Centre, London, UK
    Antivir Ther 18:213-9. 2013
  2. doi request reprint Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Laura Waters
    Department of GU HIV Medicine, Mortimer Market Centre, London, UK
    Antivir Ther 18:213-9. 2013
  3. doi request reprint A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience
    L Waters
    Department of GU HIV Medicine, Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 23:546-52. 2012
  4. doi request reprint A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine
    Laura Waters
    Chelsea and Westminster Hospital, London, UK
    AIDS 25:65-71. 2011
  5. doi request reprint Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters
    L Waters
    Department of GU HIV Medicine, Chelsea and Westminster Hospital Foundation Trust, London, UK
    HIV Med 12:289-98. 2011
  6. doi request reprint Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals
    Andrew Scourfield
    Department of HIV Medicine, Chelsea and Westminster Hospital, Chelsea, UK
    AIDS 26:1399-401. 2012
  7. doi request reprint Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers
    Marta Boffito
    Department of HIV GUM Medicine, St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 52:222-7. 2009
  8. doi request reprint The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen
    Laura Waters
    St Stephens AIDS Trust, Department of Genitourinary HIV Medicine, Chelsea and Westminster Hospital, London, United Kingdom
    Clin Infect Dis 46:1617-23. 2008
  9. doi request reprint Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays
    Saliha Yilmaz
    Cardiovascular Division, King s College London, 150 Stamford Street, London, UK
    Genomics 96:57-65. 2010
  10. ncbi request reprint Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml
    Laura Waters
    Department of Genitourinary and HIV Medicine, St Stephens Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 20:778-9. 2006

Detail Information

Publications21

  1. ncbi request reprint Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Laura Waters
    Department of GU HIV Medicine, Mortimer Market Centre, London, UK
    Antivir Ther 18:213-9. 2013
    ..We investigated the effect of an NRTI backbone in individuals receiving Pl/r after failing NNRTI-based combined antiretroviral therapy...
  2. doi request reprint Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Laura Waters
    Department of GU HIV Medicine, Mortimer Market Centre, London, UK
    Antivir Ther 18:213-9. 2013
    ..We investigated the effect of an NRTI backbone in individuals receiving PI/r after failing NNRTI-based combined antiretroviral therapy...
  3. doi request reprint A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience
    L Waters
    Department of GU HIV Medicine, Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 23:546-52. 2012
    ..The clinic has improved general practitioner (GP) liaison and facilitated closer working relationships with other specialties. Patients have reacted positively to the clinic, particularly as many do not routinely access their GP...
  4. doi request reprint A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine
    Laura Waters
    Chelsea and Westminster Hospital, London, UK
    AIDS 25:65-71. 2011
    ..Most EFV-related central nervous system (CNS) toxicity resolves early though symptoms may persist; we studied switching to etravirine (ETR) in these individuals...
  5. doi request reprint Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters
    L Waters
    Department of GU HIV Medicine, Chelsea and Westminster Hospital Foundation Trust, London, UK
    HIV Med 12:289-98. 2011
    ..We investigated whether adverse responses to highly active antiretroviral therapy (HAART) associated with late HIV presentation are secondary to low CD4 cell count per se or other confounding factors...
  6. doi request reprint Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals
    Andrew Scourfield
    Department of HIV Medicine, Chelsea and Westminster Hospital, Chelsea, UK
    AIDS 26:1399-401. 2012
    ..We aimed to describe the outcomes of individuals commencing Atripla (Gilead Sciences Inc, Foster City, California; Bristol-Myers Squibb Co, Princeton, New Jersey, USA) as a first-line regimen...
  7. doi request reprint Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers
    Marta Boffito
    Department of HIV GUM Medicine, St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 52:222-7. 2009
    ..To assess the pharmacokinetics of etravirine once and twice daily without and with a preceding efavirenz intake period in healthy volunteers...
  8. doi request reprint The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen
    Laura Waters
    St Stephens AIDS Trust, Department of Genitourinary HIV Medicine, Chelsea and Westminster Hospital, London, United Kingdom
    Clin Infect Dis 46:1617-23. 2008
    ..Viruses may be R5 tropic, X4 tropic, or dual/mixed (D/M) tropic. R5-tropic virus predominates at high CD4 cell counts, with the number of X4-tropic strains increasing as CD4 cell count decreases...
  9. doi request reprint Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays
    Saliha Yilmaz
    Cardiovascular Division, King s College London, 150 Stamford Street, London, UK
    Genomics 96:57-65. 2010
    ..Lower expression levels of these 4 candidate genes, known to play a critical role in inflammation, lipid metabolism and atherosclerosis, may explain ritonavir adverse effects in patients...
  10. ncbi request reprint Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml
    Laura Waters
    Department of Genitourinary and HIV Medicine, St Stephens Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 20:778-9. 2006
    ..Amplification was significantly more likely for 200-1000 copies/ml than 50-200 copies/ml; most samples amplified successfully, supporting the use of genotyping for low-level viraemia...
  11. doi request reprint Drug combinations for HIV: what's new?
    Andrew Scourfield
    1st Floor, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    Expert Rev Anti Infect Ther 9:1001-11. 2011
    ..This article will focus on the evidence for current therapies and strategies in ART-naive individuals and the potential for use of novel agents in the future...
  12. doi request reprint Late HIV presentation: epidemiology, clinical implications and management
    Laura Waters
    St Stephens Research, St Stephens Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London, UK
    Expert Rev Anti Infect Ther 9:877-89. 2011
    ..Finally, strategies to increase HIV testing uptake to reduce late presentation will be summarized...
  13. ncbi request reprint Cryptococcal disease and HIV infection
    Laura Waters
    Chelsea and Westminster Hospital, 369 Fulham Road, SW11 5AJ, UK
    Expert Opin Pharmacother 6:2633-44. 2005
    ..This article reviews the epidemiology, clinical features and management of cryptococcal disease in HIV-infected patients, particularly focusing on the history of, current guidelines for and future developments in antifungal therapy...
  14. ncbi request reprint The use of caspofungin in HIV-infected individuals
    Laura Waters
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Expert Opin Investig Drugs 16:899-908. 2007
    ..Finally, evidence for the use of caspofungin for the treatment of Pneumocystis jiroveci pneumonia, an unlicensed indication, including a case series from our own unit is explored...
  15. ncbi request reprint Abacavir/lamividune combination in the treatment of HIV-1 infection: a review
    Laura Waters
    St Stephen s Centre, Chelsea and Westminster Hospital, London, SW10 9NH, UK
    Expert Opin Pharmacother 7:2571-80. 2006
    ..This article reviews the pharmacology, efficacy, resistance profiles, safety and tolerability of abacavir focussing on its use in combination with lamivudine and discusses the role of this nucleoside backbone in antiretroviral therapy...
  16. ncbi request reprint Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda
    Laura Waters
    St Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 46:590-3. 2007
    ..We investigated filter paper transfer (FPT) of whole blood and plasma as an alternative to standard plasma-based assays for virologic monitoring in Uganda...
  17. ncbi request reprint Tenofovir and didanosine: a dangerous liaison
    Laura Waters
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 15:403-6, 413. 2005
  18. ncbi request reprint New therapeutic options for hepatitis C
    Laura Waters
    Department of GU and HIV Medicine, Chelsea and Westminster Hospital, London, UK
    Curr Opin Infect Dis 19:615-22. 2006
    ..New technologies for the in-vitro study of drugs have accelerated progress markedly, previously hampered by the lack of cell-culture systems or animal models for hepatitis C...
  19. ncbi request reprint Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events
    Justin Stebbing
    Department of HIV Medicine, Chelsea and Westminster Hospital, London, United Kingdom
    Clin Infect Dis 41:906-11. 2005
    ..In conclusion, there was an increased number of adverse events in coinfected individuals, compared with individuals infected with HIV-1 alone...
  20. ncbi request reprint Contraception and HIV: what do we know and what needs to be done?
    Laura Waters
    St Stephen s Centre, Department of Genitourinary and HIV Medicine, Chelsea and Westminster Hospital, London, UK
    J Fam Plann Reprod Health Care 32:10-4. 2006
  21. ncbi request reprint HIV infection and subfertility
    Laura Waters
    Department of Genitourinary Medicine, St Stephen s Centre, London, UK
    Int J STD AIDS 18:1-6. 2007
    ..HIV-infected couples can enjoy normal, healthy lives and should have access to the same investigation and treatment as their HIV-negative counterparts. Current inequities in the treatment available must be addressed...